Brief: TRACON Announces Positive Results For Cancer Therapy From The Ongoing Phase 2 Trial

TRACON Pharmaceuticals

14/12/2022 13:19

Dec 14 (Reuters) - TRACON Pharmaceuticals Inc  TCON.O :
    * TRACON PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS BASED ON
DOUBLE-DIGIT OBJECTIVE RESPONSE RATE IN EACH COHORT FROM THE
ONGOING ENVASARC PHASE 2 PIVOTAL TRIAL
    * TRACON PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS BASED ON
DOUBLE-DIGIT OBJECTIVE RESPONSE RATE IN EACH COHORT FROM THE
ONGOING ENVASARC PHASE 2 PIVOTAL TRIAL
    * TRACON PHARMACEUTICALS INC- OBJECTIVE RESPONSE RATE (ORR)
ACHIEVED IN EACH COHORT AT INTERIM EFFICACY ANALYSIS THAT
EXCEEDED FUTILITY THRESHOLD
    * TRACON PHARMACEUTICALS INC- ENROLLMENT CONTINUES AHEAD OF
SCHEDULE
    * TRACON PHARMACEUTICALS INC- NEXT INTERIM ANALYSIS EXPECTED
IN
MID-2023 WITH FULL ACCRUAL NOW EXPECTED BEFORE END OF 2023
    * TRACON PHARMACEUTICALS INC- ARBITRATION DECISION EXPECTED
IN 1Q
2023 HAS POTENTIAL TO INCREASE CASH RUNWAY

Source text for Eikon:  ID:nGNXbQKv5 
Further company coverage:  TCON.O 
 ((Reuters.Briefs@thomsonreuters.com;))